Navin Fluorine International Ltd (NAVINFLUOR) Q1 FY27 Earnings Call: Turns Net Debt-Free, Confirms $100M CDMO Target

Navin Fluorine International Ltd held its Q1 FY27 earnings call on August 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Revenue and Profitability Across the Board

• Consolidated revenue of Rs.1,045 Cr in Q1 FY 2026-2027, up 44% YoY, driven by strong performance across all three verticals.
• Operating EBITDA of Rs.357 Cr at a 34.2% margin, expanding 566 bps YoY and reflecting operating leverage from volume growth.
• PAT of Rs.243 Cr for Q1 FY 2026-2027, surging 108% YoY on the back of higher operating profit and a net debt-free balance sheet achieved during the quarter.
• Operating cash flow of Rs.173 Cr in Q1 FY 2026-2027; net working capital stood at 81 days of sales.
• Net debt-free position reached during Q1 FY 2026-2027, providing balance sheet flexibility for the ~Rs.3,000 Cr capex pipeline over FY 2027-2030.

Broad-Based Growth Led by HPP and CDMO

• HPP revenue of Rs.540 Cr in Q1 FY 2026-2027, +33% YoY, supported by healthy volume growth and improved realizations in a constructive pricing environment for refrigerants.
• Specialty chemicals revenue of Rs.325 Cr, +48% YoY, driven by five new molecules (three patented) with volume-led growth and minimal pricing contribution; pricing pressure persists in the LatAm market.
• CDMO revenue of Rs.180 Cr, +82% YoY, with management confirming the previously guided $100 million CDMO revenue target for FY 2026-2027 is "pretty much on track."
• HPP+CDMO combined contribution mix improved to 69% in Q1 FY 2026-2027 from 62% in Q4 FY 2025-2026, yet group EBITDA margins remained stable at ~32-33% due to raw-material inflation and a lag in price pass-through.
• Specialty volume recovery underway but management stated the philosophy is "not to return to the old 30% EBITDA margin," instead focusing on productivity and MPP plant bottlenecking for a 2x capacity turn.

Deepening European Partnership, Scaling Toward FY29

• Active pipeline of 30-40 molecules, with ~10 in late stage; management expects 3-4 late-stage molecules to receive FDA readout over the next 8-12 months (through mid-FY 2027-2028), serving as a catalyst for new customer wins.
• New CDMO capacity dedicated to an existing European partner, moving Navin Fluorine to an API minus one level within the same supply chain; an early-phase molecule for the same customer broadens the portfolio further.
• Working relationships with all top 20 global pharma companies, with 3-4 molecules under development across different global majors across cardiovascular, respiratory, oncology, animal health, and neuro therapeutic areas.
• Rs.288 Cr CGMP 4 capex targeting 3x asset turns, implying ~ Rs.900 Cr revenue from that facility combined with phase 2 by FY 2028-2029; this is over and above existing phase 1 and phase 3 revenue.
• CDMO Phase 2 capex of Rs.125 Cr (internal accruals) expected to operationalize by Q4 FY 2026-2027; consolidated minus standalone EBITDA margin (NFASL subsidiary) dropped to 32% in Q1 FY27 from 40-45% due to quarterly campaign mix and AHF commissioning, with downstream expansions expected to improve subsidiary margins later.

Incubating a Material Business Unit by End of Decade

• Rs.90 Cr adoption capex approved (internal accruals) for advanced materials, targeting completion by Q2 FY 2027-2028; five products already lab-qualified for commercial-scale production with orders in hand, and four to five more in the pipeline for the next phase.
• Chairman Vishad Mafatlal stated the advanced materials vertical incubation strategy targets it "to become a material business unit by the end of the decade, comparable to the CDMO business of today."
• Navin Fluorine is the only supplier to Chemours for a two-phase liquid cooling product; Chemours recorded $1 million in sales from this product in Q1 FY 2026-2027, and management reiterated a 15-month timeline remains valid for scale-up updates.
• DRDO partnership under a TDF project (Ministry of Defence) for an indigenous specialty material, contributing to Atmanirbhar Bharat; no financial details or timelines were disclosed, though management noted applications beyond defense represent "a material opportunity."
• Applications span data centers, electronics, semiconductors, defense, OLEDs, fire suppressants, and new energy; the Kimos liquid cooling project is targeted for completion by end of Q2 FY 2026-2027.

Disciplined Allocation, Margin Resilience Through Operating Leverage

• EBITDA margin guidance of 32-33% (±~1%) for the near term (FY 2026-2027 to FY 2027-2028), supported by fixed-cost productivity and operating leverage from new HFC capacity, debottlenecking, and the KEMOS project.
• Gross margins dipped ~100 bps sequentially in Q1 FY 2026-2027 due to raw-material inflation; fixed-cost productivity improvements offset the impact, keeping EBITDA within the guided range.
• ~Rs.3,000 Cr capex planned over the next 3-4 years (FY 2026-2027 through FY 2029-2030), on top of ~Rs.3,000 Cr spent over the past 5 years (FY 2021-2022 to FY 2025-2026).
• Stage-gated capex process with technical evaluation, commercial clearance, and board thresholds; product capex is based on customer engagement (not firm purchase orders), while service contracts like KEMOS are backed by order projections and commitments.
• Renewable energy investment of Rs.15.73 Cr in a group captive hybrid project for 14.9 MW; expected to meet more than 60% of energy requirements, supporting EBITDA margins in any pricing environment.

Positioning for a Supply-Driven Pricing Inflection Post-2027

• R32 capacity expansion to 15,000 metric tons (added to existing 9,000-10,000 tonnes) on track for commissioning in Q3 FY 2026-2027; peak revenue guidance of Rs.600-Rs.825 Cr based on original asset-turn assumptions.
• Management targeting 35-45% of total R32 capacity to be contracted for a five-year period beyond FY 2026-2027, with advanced customer conversations underway; a balanced approach maintaining some open position over the next 5 years.
• India expected to be oversupplied for the next five years (roughly FY 2026-2027 through FY 2030-2031), but capacity will service export markets; management sees pricing benefits emerging "beyond calendar 2027" post-China quota cuts in January 2028.
• Long-term R32 demand constructive — management cited global context where "demand is expected to double over the next decade while quota-driven supply shrinks to half," positioning Navin Fluorine as a low-cost producer with integrated HF value chain.
• AHF capacity of 60,000 tonnes across Surat and Dahej is expected to be sufficient for the next 4-5 years (from FY 2026-2027); management may consider expansion if needed and will focus on downstream value-added products and fluorination capability for advanced materials.